Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30558395 | 0.98 | MPO (0.43) | MPOACHECYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL28459720 | 0.75 | ACHE (0.41) | MPOACHECYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL15818200 | 0.73 | MPO (0.74) | MPOCYP1A2ALDH1A1ABCB1ELANE | |
| Hydrochloric Acid SCHEMBL11078111 | 0.72 | MPO (0.72) | MPOCYP1A2ALDH1A1ABCB1ELANE | |
| Hydrochloric Acid SCHEMBL11085129 | 0.71 | ABCB1 (0.51) | MPOACHECYP1A2ALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL11078947 | 0.69 | MPO (0.55) | MPOALDH1A1ABCB1 | |
| SCHEMBL17361766 | 0.69 | ABCB1 (0.43) | MPOCYP1A2ALDH1A1CYP3A4MEN1 | |
| SCHEMBL1274286 | 0.68 | ALDH1A1 (0.55) | ACHECYP1A2ALDH1A1CYP3A4MEN1 | |
| SCHEMBL17361717 | 0.68 | ABCB1 (0.42) | MPOCYP1A2ALDH1A1CYP3A4ABCB1 | |
| Hydrochloric Acid SCHEMBL30558491 | 0.68 | ABCB1 (0.42) | MPOCYP1A2ALDH1A1CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3160952-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3160952-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3741749-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3741749-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3738960-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3738960-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10385047-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385047-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10106534-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180251458-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-09-06 | — | — | US | disclosed |
| US-20160107995-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160107995-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| US-9242968-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242968-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242968-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150376169-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20150376169-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20150376169-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-12-31 | — | — | US | disclosed |
| WO-2015200709-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015200709-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376169-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM6A, KDM1A | MPO 996/4885ACHE 1269/4885CYP1A2 2906/4885 |
| US-20180251458-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM6A, KDM1A | MPO 996/4885ACHE 1269/4885CYP1A2 2906/4885 |
| US-20160107995-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM6A, KDM1A | MPO 996/4885ACHE 1269/4885CYP1A2 2906/4885 |
| US-10106534-B2 | Histone demethylase inhibitors | KDM1B, KDM6A, KDM1A | MPO 996/4885ACHE 1269/4885CYP1A2 2906/4885 |
| US-10385047-B2 | Histone demethylase inhibitors | KDM1B, KDM6A, KDM1A | MPO 996/4885ACHE 1269/4885CYP1A2 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.